Business Wire

CIRIUM

Share
Airline Passenger Capacity is Projected to Grow at 47% in 2022

Global aviation analytics firm Cirium, has released its second annual Airline Insights Review, which reveals an industry in recovery and poised for a projected 47% growth in capacity (the number of seats flown) in 2022. This steep increase indicates capacity could return to 2015 levels by the end of next year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005398/en/

Last year, the pandemic and its consequences wiped out 15 years of global passenger capacity growth—based on the total number of seats flown—in a matter of months, reducing 2020 capacity flown to levels last seen in 2005.

Although recovery was varied in 2021, global capacity is forecasted to return to capacity levels seen in 2006 by the end of the year.

Regions with strong domestic markets showed accelerated recovery this year—in particular, in the US and China. In fact, Chinese domestic flights are up 6% compared to pre-pandemic levels in 2019.

Of all the flights tracked January to October 31 worldwide, 78% were domestic flights. International flights experienced a slow recovery with many restrictions in place until Q4 of 2021, and some restrictions still in place, depending on the routes. Indeed, international flights saw a 6% growth in 2021 compared to the same period in 2020.

“The past year has had its challenges as we continued to face fluctuating cases of COVID-19, new variants—most recently Omicron—and varied vaccination programs per country. There is light at the end of the tunnel as we see international travel corridors reopening. However, we will continue to track this momentum as new variants arise and we hope the invaluable analyses in our Airline Insights Report help to navigate what’s to come,” said Jeremy Bowen, CEO of Cirium.

Cirium predicts a year of acceleration in 2022

“Cirium’s experts have analysed 2021 data and formulated forecasts for 2022 and beyond. Near the end of 2022, global capacity will return to 2015 levels, as we see a steep increase in more seats returning to the skies.

“In Cirium’s Airline Insights Report, we have included Seven Things to Look for in 2022 to enable the industry to gain insight into these forecasts and use them to anticipate market developments and make well-informed decisions,” Bowen added.

As more passengers steadily return to the skies, this will mean worldwide domestic traffic (measured in passenger numbers) is predicted to be back to pre-pandemic levels by the end of 2022. International passenger traffic is likely to reach two-thirds of 2019 levels.

Cirium projections show that the global passenger fleet in service will increase to 20,700 by the end of 2022—only a few hundred less than at the end of 2019—pre-pandemic.

The slow recovery of business travel seen so far will change in 2022, with predictions from the industry that there will be a 36% surge in business travel year-over-year. According to Cirium data, business events being tracked online are already increasing for next year.

Conversions of passenger jets to freighters will continue to increase and in 2022, with a potential total of 160 passenger jets converted to freighters—surpassing previous conversion figures.

Aircraft values and lease rates took an unprecedented hit in the past 12 months, however Cirium suggests that they’ve reached the bottom as the values and lease rates for many aircraft types have stabilized and a few are improving. Some aircraft types remain on watch next year, including the Airbus A350 and the Boeing 787.

Cirium anticipates that airlines will increasingly rely on partnerships to carry passengers into partner home markets in 2022. This will mean a shift in airlines flying secondary markets post-pandemic and instead see them taking advantage of their airline partners to fly passengers to secondary cities.

As more flights return to the skies, it’s no surprise that CO2 emissions will increase next year—the CO2 emissions from flights in 2021 were 40% less than pre-pandemic. However, airlines are returning more fuel-efficient fleets to service and sustainability has become front and center in aviation, with many looking at fuel burn and how to reach net zero 2050 targets.

“Cirium anticipates the return to normalcy will usher in more focus on sustainable travel practices, including younger, more fuel-efficient aircraft, and the ability to more closely measure the impact of airline travel on global greenhouse gas emissions,” said Bowen.

To read the full Cirium Airline Insights Review 2021, including the seven predictions of 2022 – click here .

The 2021 Airline Insights Report is Cirium’s collection of expert analyses covering a wide range of topics surrounding airlines at the core and the aviation industry that encircles them. The report covers:

  • Top routes flown and airports in 2021
  • The current state of the global passenger traffic, capacity and fleet
  • Sustainability initiatives in the airline industry
  • Airline startups and new routes flown in 2021
  • Average airfares in key markets
  • Spotlights on APAC and Latin America

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye